App-Quantinova.ai

Dynamics of circulating tumor cells during the course of chemotherapy and prognostic relevance across molecular subtypes in high-risk early breast cancer patients Results from the adjuvant SUCCESS A trial

MLJ Tzschaschel - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Cyclophosphamide

Evaluation of subclonality in the CTC and DTC compartment of patients with metastatic breast cancer using low pass whole genome and AmpliSeq panel sequencing

A Brouwer - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

TP53

Evaluation of HER2 expression and amplification on CTCs using DEPArray analysis and sorting followed by FISH

A Brouwer - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

BT-20

A hierarchy of cancer associated fibroblasts in situ and in circulation promote breast cancer metastasis

U Sharma - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

SDF-1

Clinical value of Zr-trastuzumab PET in HER2-positive breast cancer patients with a clinical dilemma

CP Schröder - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Trastuzumab

BRCA1-IRIS overexpression promotes and maintains the tumor initiating phenotype in TNBC cells: Implications for breast cancer early lesions

A Sinha - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

DE-074

Identifying metastatic drivers in patient derived xenograft models of triple negative breast cancer

E Powell - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Triple-negative breast cancer

N/A

Serum levels of RANKL are increased in primary breast cancer patients in the presence of disseminated tumor cells in the bone marrow

S Kasimir-Bauer - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bone metastases

N/A

Circulating tumor cell clusters-associated gene plakoglobin is a novel prognostic predictor in patients with breast cancer

W Goto - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Cyclophosphamide

High reduction of circulating tumour cells in HER2-negative locally advanced or metastatic breast cancer (LAMBC) patients treated with eribulin as third line chemotherapy (ONSITE study)

L Manso Sánchez - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Estrogens

IMENEO: International MEta-analysis of circulating tumor cell detection in early breast cancer patients treated by NEOadjuvant chemotherapy

F-C Bidard - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Active surveillance with a combination of tumor marker CA27.29 and detection of circulating tumor cells two year after primary diagnosis strongly predicts subsequent prognosis

W Janni - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Profiling miRNA in high risk post-operative early breast cancer patients to detect possible association to correlation with immune system antitumor response

MLJ Tzschaschel - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Paclitaxel induced mena- and TMEM-mediated pro-metastatic changes in the breast cancer microenvironment

GS Karagiannis - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Cyclophosphamide

An optimized workflow to analyze mutations in both circulating cell-free and circulating tumor cell DNA by digital PCR

SR Vitale - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

CNIO-BR-008 trial: Reversion of T-cell exhaustion caused by chronic treatment with hypoxia-inducing antiangiogenic treatment by durvalumab in HER2-negative breast cancer: A pilot proof-of-concept trial

M Quintela-Fandino - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Bevacizumab

Signal-To-Noise Ratio and Acquisition Duration Explain Erroneous Mean Transit Times in Acute Stroke Computed Tomography Perfusion Imaging

Koshuke Kudo - American Heart Association (AHA) , 2012

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Stroke

N/A

ON MICROCIRCULATORY BIOMARKERS OF SECONDARY CEREBRAL ISCHEMIA AT TRAUMATIC BRAIN INJURY

Denis Bragin - National Neurotrauma Society (NNS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Traumatic brain injury

N/A

CTC AND CTDNA ASSAYS REVEAL COMPLIMENTARY INFORMATION FOR METASTATIC UROTHELIAL CANCER PATIENTS

Heather Chalfin - American Urological Association (AUA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced Urothelial Carcinoma

N/A

CIRCULATING TUMOR CELLS ARE A STRONG PREDICTOR OF CANCER SPECIFIC SURVIVAL IN HIGH RISK NONMUSCLE INVASIVE BLADDER CANCER: FINAL ANALYSIS OF A PROSPECTIVE OBSERVATIONAL STUDY

Gian Maria Busetto - American Urological Association (AUA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

N/A

Filters

1671 Abstracts